Using RNAi to target FLT3 in AML, an important mediator of survival, proliferation, and differentiation of blasts, siRNA treatment in combination with a small molecule inhibitor was more effective for treatment than either method alone [22]. The gene discussed is FLT3; the disease is acute myeloid leukemia.